

Diversity of *vir* Genes in *Plasmodium vivax* from Endemic Regions in the Republic of Korea: an Initial Evaluation

Ui-han Son^{1,2}, Sylvatrie-Danne Dinzouna-Boutamba¹, Sanghyun Lee³, Hae Soo Yun¹, Jung-Yeon Kim⁴, So-Young Joo¹, Sookwan Jeong¹, Man Hee Rhee⁵, Yeonchul Hong¹, Dong-Il Chung¹, Dongmi Kwak^{2,*}, Youn-Kyoung Goo^{1,*}

¹Department of Parasitology and Tropical Medicine, Kyungpook National University School of Medicine, Daegu 41944, Korea; ²Laboratory of Parasitology, College of Veterinary Medicine, Kyungpook National University, Daegu 41566, Korea; ³Pathogen Resource TF, Center for Infectious Diseases, Korea National Institute of Health, Korea CDC, Chungbuk 28159, Korea; ⁴Division of Malaria and Parasitic Diseases, National Institute of Health, Korea CDC, Chungbuk 28159, Korea; ⁵Laboratory of Veterinary Physiology & Cell Signaling, College of Veterinary Medicine, Kyungpook National University, Daegu 41566, Korea

Abstract: Variant surface antigens (VSAs) encoded by *pir* families are considered to be the key proteins used by many *Plasmodium* spp. to escape the host immune system by antigenic variation. This attribute of VSAs is a critical issue in the development of a novel vaccine. In this regard, a population genetic study of *vir* genes from *Plasmodium vivax* was performed in the Republic of Korea (ROK). Eighty-five venous blood samples and 4 of the *vir* genes, namely *vir* 27, *vir* 21, *vir* 12, and *vir* 4, were selected for study. The number of segregating sites (S), number of haplotypes (H), haplotype diversity (Hd), DNA diversity (π and Θ_w), and Tajima's D test value were conducted. Phylogenetic trees of each gene were constructed. The *vir* 21 (S = 143, H = 22, Hd = 0.827) was the most genetically diverse gene, and the *vir* 4 (S = 6, H = 4, Hd = 0.556) was the opposite one. Tajima's D values for *vir* 27 (1.08530, $P > 0.1$), *vir* 12 (2.89007, $P < 0.01$), and *vir* 21 (0.40782, $P > 0.1$) were positive, and that of *vir* 4 (-1.32162, $P > 0.1$) was negative. All phylogenetic trees showed 2 clades with no particular branching according to the geographical differences and cluster. This study is the first survey on the *vir* genes in ROK, providing information on the genetic level. The sample sequences from *vir* 4 showed a clear difference to the Sal-1 reference gene sequence, whereas they were very similar to those from Indian isolates.

Key words: *Plasmodium vivax*, *vir* gene, genetic diversity, the Republic of Korea

INTRODUCTION

Plasmodium vivax is the most prevalent human malaria parasite causing most of the cases occurring outside of sub-Saharan Africa [1,2]. Vivax malaria only infects host reticulocytes, the precursor of erythrocytes, whereas *Plasmodium falciparum* infects all stages of erythrocytes [3]. This narrow range of infection ability of *P. vivax* gives it the stereotype of mild-type malaria. Until now, vivax malaria has been overlooked because of its mild characteristics compared with severe falciparum malaria [4]. However, contrary to the benign reputation of vivax malaria, its clinical manifestations are not very mild, inciting chronic infection with hypoproteinemia, edema, and coma. Furthermore, the patients with vivax malaria and concurrent

nutrient deficiency can suffer from splenic rupture, which and at last, may result in death [5-7].

Since 1993, *P. vivax* has been consistently present in the northern areas of Gyunggido (Province) and Gangwon-do, Republic of Korea (ROK) [8,9]. Soldiers (30.5%) and veterans (25.1%) of the ROK make up over a half of the malaria patients in the country [10]. Residents (including civilians and soldiers) living near the demilitarized zone (DMZ) on the northern border of the ROK have also been infected with *P. vivax*. In this regard, chloroquine and primaquine have been used as a prophylactic measurement for the soldiers of the endemic area. However, such massive chemoprophylaxis using both drugs leads to a concern on an occurrence of antimalarial drug resistant *P. vivax* in ROK.

Ever since chloroquine-resistant *P. vivax* (CRPv) was first reported in Papua New Guinea [11], such strain has been reported in many other places, including India, Vietnam, and even Bolivia of South America [4,12-14], with spread occurring globally within decades. This expansion of CRPv demonstrates that once an antimalarial drug-resistant strain develops, it would

•Received 19 June 2016, revised 15 February 2017, accepted 19 February 2017.

*Corresponding author (dmkwak@knu.ac.kr; kuku1819@knu.ac.kr)

© 2017, Korean Society for Parasitology and Tropical Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

soon become an international problem. Therefore, the development of malaria vaccines is receiving an attention as an alternative way to prevent vivax malaria.

By virtue of their antigenic variation, variant surface antigens (VSAs) of many *Plasmodium* spp. are considered to be the key proteins used to escape from the host immune system through antigenic variations [15]. These proteins are coded by multi-gene families located on telomeric and subtelomeric regions of the parasite's chromosomes. The *var* and variant interspersed repeats (*vir*) gene superfamilies have been recognized in *P. falciparum* and *P. vivax*, respectively [16]. The 346 *vir* genes are divided into 12 subfamilies, named A to L [17,18], and are reported to be related to host immune system evasion [5]. In addition, the *vir* proteins were revealed to be exported to the infected erythrocyte's surface and partially induce the adherence of *P. vivax*-infected reticulocytes to the endothelial cell receptor [19,20]. All together, these data suggest that the VSAs encoded by the *vir* genes could be candidate targets for vaccine development, but the lack of an in vitro culture system for *P. vivax* and the variant nature of VSAs have been an obstacle to the development of a potent vaccine [21].

Trials for developing vaccines against *var*-encoded proteins have been partially established, dismissing the skepticism over caused by the variance of *var* proteins [22]. By disrupting the erythrocyte rosettes, protection against sequestration could be established [23]. Like the *var* genes, *vir* genes are potential targets for vaccination against vivax malaria [17]. Although researching the genetic variation of VSAs is critical in the development of a novel vaccine, there has been no investigation on the subject until now in the ROK. Previously, Gupta et al. [7,24,25] investigated the diversity of *P. vivax* populations from various regions in India with *vir* genes. Here, we performed a population genetic study in ROK. Among *vir* genes, the *vir* 27, *vir* 21, *vir* 12, and *vir* 4 sequences on the subtelomeric area were more specifically analyzed. This study will provide a better understanding of the diversity of *vir* genes.

MATERIALS AND METHODS

Ethics

The study was approved by the Ethics Committee of the Kyungpook National University. An approval form was used to obtain written informed consent from each participant. Each participant also consented to provide a 5-ml blood sample.




Fig. 1. Blood collection regions. From left to right, Gimpo (GP), Paju (PJ), and Choerwon (CW) are denoted by asterisks.

Sample collection

A total 85 venous blood samples were collected in the northern part of ROK, which are already known as malarial endemic regions [9], from 2011 to 2013. The samples included 5 from Gimpo (GP), 2 from Paju (PJ), and 15 from Cheorwon (CW) in 2011; 6 from GP, 23 from PJ, and 7 from CW in 2012; and 10 from PJ and 17 from CW in 2013 (Fig. 1). The collection criterion was the patient living in the study area who showed tertian fever. The blood samples were kept in EDTA-treated tube and cooled in -70°C .

Diagnosis of vivax malaria

Rapid diagnostic test kits (RDTs) (NanoSign Malaria P.f/P.v from Bioland, Cheonan, Korea, and SD Bioline Ag P.f/pan Rapid from SD, Hwaseong-si, Korea) were used for the first screening. Subsequently, microscopic examinations and nested PCR were performed to confirm the tentative diagnosis of vivax malaria. The microscopic tests were performed with a thick and thin blood films stained with Giemsa, and nested PCR targeting 18S rRNA was performed as previously described [26].

DNA extraction

Genomic DNA of *P. vivax* was extracted from 200 μl of each blood sample using a QIAamp DNA Mini Kit (Qiagen, Valencia, California, USA) following the manufacturer's instructions. The extracted DNA was preserved in -70°C until required.

PCR amplification of vir genes

Four of the vir genes, named vir 27, vir 21, vir 12, and vir 4, were selected (Table 1). Compared with vir 27, which belongs to subfamily I, vir 4 of subfamily C and vir 21 of subfamily B have variants with more polymorphic and distributed conserved blocks within the sequences, whereas vir 12 of subfamily E is considered to be more conserved but shown high diversity among previous studies conducted on Indian isolates [24,25]. These *P. vivax* sequences were amplified according to the following protocol. Each vir gene was amplified by primary and nested PCR with 4 primers for vir 27, vir 21, and vir 4, and 3 primers for vir 12, respectively. The primary PCR mixture contained 2.5 µl of 10× buffer, 2 µl of dNTPs, 1 µl of forward primer, 1 µl of reverse primer, 0.25 µl of Ex taq polymerase (Takara, Shiga, Japan), 1 µl of DNA template, and distilled water to make up the volume to 25 µl. The semi-nested PCR was performed with a similar ratio of components but with 2 µl of DNA template. The primary PCR cycle was 95°C for 5 min; 35 cycles of 95°C for 30 sec, 55°C for 30 sec, and 72°C for 1 min; and a final extension of 72°C for 7 min. The semi-nested PCR had 30 cycles of the annealing step. Electrophoresis was performed on a 1.5% agarose gel with 50 mg/ml ethidium bromide. Ladders used were 100 bp for vir 27, vir 4, and vir 21, and 1 kb for vir 12.

Purification of PCR products and sequencing of vir genes

Amplicons were purified with an AccuPrep® Gel Purification Kit (Bioneer, Daejeon, Korea) for cloning, according to the manufacturer's instructions. After gel purification, the PCR products were ligated into the pGEM-T TA cloning vector (Promega, Madison, Wisconsin, USA) and transformed into *Escherichia coli* DH5α competent cells. Five colonies with the recombinant plasmids per each vir gene were selected, and then, sequenced with the pUC/M13 forward and reverse primers by using a Big-Dye Terminator ver. 3.1 sequencing kit (Applied Biosystems, Foster City, California, USA) with an automatic ABI3730 DNA Analyzer sequencer (Applied Biosystems).

Sequence analysis

Acquired sequences were aligned by the Clustal Omega multiple alignment function of BioEdit [27]. The segregating sites (S), the number of haplotypes (H), haplotype diversity (Hd), the average number of pairwise nucleotide differences (π), and the total number of segregating sites (Θ_w) were evaluated by using DnaSP ver. 5.10.01 [28].

The π and the Θ_w values were used to estimate the genetic diversity. The π value indicates the randomness of the sample, whereas the Θ_w value indicates the equilibrium of gene segregating sites in a population [29,30]. These 2 measures are also

Table 1. Information of PCR ingredients used in this study

PCR primers	Primer sequence	Annealing temperature (°C)	Subfamily ^a	Gene length ^b (bp)	Accession no.
v27_1	vir 27 gene: PVX 102630 TGGCATTACACTTAGCGGTAT	55	I	1,255	AAKM01000041.2
v27_4	TGGTGTATCTGTGTGAAGATTTG				
v27_2	CATTTTGAGCACGTTCTCCTT				
v27_3	TCAAGTTGTAAGGTGATCAATGAAA				
v21_1	vir 21 gene: PVX 115480 ACAACCTCATTGGTATTTACATTTATGA	55	B	974	AAKM01000003.1
v21_4	TGCGAAAAATAAGACGCAAA				
v21_2	TTCAAAGCATAAAATTCGCACT				
v21_3	TCCCAAATAAAGGCAAGGTT				
v12_1	vir 12 gene: PVX 097525 AAATATTCAAACAATGGCAATACA	55	E	2,548	AAKM01000016.1
v12_3	ACTTCCCGTGCAGGTATTTT				
v12_2	TGACATAGGTAACGCATAATATAGCA				
v4_1	vir 4 gene: PVX 021680 CGAAATATACTTGTCTTAAGTGGTTG	55	C	1,314	AAKM01000104.1
v4_4	CAGAATGGCATCTGTTTATGC				
v4_2	GACCAATATTTTGGGCAGGTT				
v4_3	AGGTAGAATTGCGGCTCAGA				

^asubfamily of the vir gene.

^bamplicon size.

compared as a test of neutrality. Tajima's D test of neutrality was done with the sliding window option (window length, 100 bp; step size, 25 bp) for distinguishing whether the *P. vivax* DNA evolved randomly, neutrally, or not, including balancing selection or directional selection [31]. This test was calculated with DnaSP ver. 5.10.01. Any differences in the mean values were considered to be statistically significant when at $P < 0.05$.

Phylogenetic analysis

The *vir* genes of *P. vivax* Sal-1 (GenBank accession nos. AAKM01000041.2 for *vir* 27, AAKM01000104.1 for *vir* 4, AAKM01000016.1 for *vir* 12, and AAKM01000003.1 for *vir* 21) were used as the reference. Using the minimum-evolution method and maximum composite likelihood model option, the ROK *vir* gene sequences were compared with the Sal-1 references, and phylogenetic trees were constructed using MEGA 7.0 [32]. Each node in the trees was supported by bootstrap analysis with 1,000 repetitions. The subjects of the phylogenetic trees are labeled with the name of the gene, sample number, collected year, and region.

RESULTS

Nested-PCR results

The nested-PCR results were evaluated according to the year and region collected as shown in Table 2. The *vir* 27 gene revealed the highest PCR-positive rate (72.9%), followed by *vir* 12 (65.7%), *vir* 21 (46.7%), and *vir* 4 (31.3%).

Specifically, *vir* 27 was amplified in 59.1% (13/22), 80.6% (29/36), and 74.1% (20/27) of the samples collected in 2011,

2012, and 2013, respectively. According to the sample collection year, samples from 2012 showed the highest PCR-positive rate (80.6%). Per classification by region, the GP samples had the highest rate of PCR-positive results (81.8%).

For *vir* 21, 43 samples that were composed of 50.0% (11/22), 47.2% (17/36), and 55.6% (15/27) of the samples collected in 2011, 2012, and 2013, respectively, were amplified indicating that these samples were PCR positive. Gene was most prevalent in the samples of 2011 and 2013. Samples from PJ and CW had the highest PCR-positive rates (54.3% and 51.3%, respectively).

For *vir* 12, 50.0% (11/22), 83.3% (30/36), and 66.7% (18/27) of the samples collected in 2011, 2012, and 2013, respectively, were PCR positive, showing 2012 to have the highest prevalence for this gene. Samples from PJ showed the highest PCR-positive rate at 74.3%.

For *vir* 4, 22.7% (5/22), 36.1% (13/36), and 29.6% (8/27) of the samples collected in 2011, 2012, and 2013, respectively, were PCR positive, again with 2012 having the highest rate for this gene. The PCR-positive rate of the GP samples was higher than that of PJ and CW (36.4%, 25.7%, and 33.3%, respectively). Gene *vir* 4 showed the lowest positive rate on PCR.

Variable surface protein 27 gene

Compared with the Sal-1 reference sequence, 62 *vir* 27 genes showed 10 S, 2 of them being singleton variable sites and 8 of them being parsimony-informative sites. The nucleotide variations T93C, G101A, C228T, T256C, A257G, A259G, G262A, A590C, T741C, and A753G were separately found (Fig. 2A). The sequences of *vir* 27 genes are available in GenBank (nos.

Table 2. PCR results of venous blood samples collected from malaria patients according to year of collection and region

Year	Region	<i>Vir</i> 27		<i>Vir</i> 21		<i>Vir</i> 12		<i>Vir</i> 4	
		+	-	+	-	+	-	+	-
2011	Gimpo (GP)	5 (22.7)	0 (0.0)	1 (20.0)	4 (80.0)	2 (40.0)	3 (60.0)	2 (40.0)	3 (60.0)
	Paju (PJ)	1 (4.6)	1 (4.6)	1 (50.0)	1 (50.0)	1 (50.0)	1 (50.0)	0 (0.0)	2 (100.0)
	Cheorwon (CW)	7 (31.8)	8 (36.3)	9 (60.0)	6 (40.0)	8 (53.3)	7 (46.7)	3 (20.0)	12 (80.0)
	Total	13 (59.1)	9 (40.9)	11 (50.0)	11 (50.0)	11 (50.0)	11 (50.0)	5 (22.7)	17 (77.3)
2012	Gimpo	4 (66.6)	2 (33.3)	3 (50.0)	3 (50.0)	5 (83.3)	1 (16.7)	2 (33.3)	4 (66.7)
	Paju	18 (78.3)	5 (21.7)	12 (52.2)	11 (47.8)	19 (82.6)	4 (17.4)	6 (26.1)	17 (73.9)
	Cheorwon	7 (100.0)	0 (0.0)	2 (28.6)	5 (71.4)	6 (85.7)	1 (14.3)	5 (71.4)	2 (28.6)
	Total	29 (80.6)	7 (20.4)	17 (47.2)	19 (52.8)	30 (83.3)	6 (16.7)	13 (36.1)	23 (63.9)
2013	Gimpo	0	0	0	0	0	0	0	0
	Paju	6 (60.0)	4 (40.0)	6 (60.0)	4 (40.0)	6 (60.0)	4 (40.0)	3 (30.0)	7 (70.0)
	Cheorwon	14 (82.4)	3 (17.6)	9 (52.9)	8 (47.1)	12 (70.6)	5 (29.4)	5 (29.4)	12 (70.6)
	Total	20 (74.1)	7 (25.9)	15 (55.6)	12 (44.4)	18 (66.7)	9 (33.3)	8 (29.6)	19 (70.4)
Total	62 (72.9)	23 (27.1)	43 (46.7)	42 (53.3)	59 (65.7)	26 (34.3)	26 (31.3)	59 (68.7)	




Fig. 2. Sequence polymorphism of *vir* genes in the ROK *P. vivax* isolates. The polymorphic nucleotides were compared to that of Sal-1 (GenBank no.: AAKM01000041.2). (A) Sequences of *vir* 27 gene of isolates. (B) Sequences of *vir* 21 gene of ROK isolates compared with 5 Indian isolates. (C) Sequences of *vir* 12 gene of isolates. (D) Sequences of *vir* 4 gene of ROK and Indian isolates. The listed sequences are indicated by dots for nucleotides with sequences of Sal-1, and hyphens for gaps. The locations of polymorphic sites are represented above and the nucleotide changes are marked with colors.

Table 3. Summary statistics for the 4 *vir* genes in gene level

Vir genes (No. of analyzed genes)	Sequence length	Segregating sites (S)	No. of haplotypes (H)	Haplotype diversity (Hd)	Nucleotide diversity		Tajima's D test
					π	Θ_w	
<i>Vir</i> 27 (62)	1,255 bp	10	6	0.774	0.00238	0.00171	1.08530
<i>Vir</i> 21 (43)	974 bp	143	22	0.827	0.04165	0.03746	0.40782
<i>Vir</i> 12 (59)	1,323 bp	74	9	0.795	0.03640	0.01979	2.89007 ^a
<i>Vir</i> 4 (26)	1,314 bp	6	4	0.556	0.00064	0.00116	-1.32162
Average		58.25	10.25	0.738	0.02027	0.01503	0.76539

^aStatistical significance, $P < 0.01$.

KY608472-608521). The H value for *vir* 27 was 6, and the Hd value was 0.774.

Nucleotide diversity values of *vir* 27 were 0.00238 and 0.00171 for π and Θ_w , respectively (Table 3; Supplement Fig. 1). Tajima's D value of *vir* 27 was positive (1.08530, $P > 0.1$; Table 3; Supplement Fig. 2).

The *vir* 27 gene from the 62 ROK samples was divided into 2 distinct clades in phylogenetic analysis. One clade was comprised of 45 samples, including Sal-1 reference gene, and was divided into several subclades which consisted of 18 samples. In the clade of 45 samples, the main subclade was composed of 21 samples, and the other subclade was further composed of 2 clades with 10 samples each and 1 clade with 4 samples (Supplement Fig. 3A).

Variable surface protein 21 gene

There were 43 samples PCR positive for *vir* 21 genes. A total of 143 S were found, including 55 singleton sites with 2 variants, only 1 singleton sites with 3 variants, 84 parsimony-informative sites with 2 variants, and 3 parsimony-informative sites with 3 variants (Fig. 2B). The sequences of *vir* 21 genes are available in GenBank (nos. KY608420-608471). The H and Hd values were 22 and 0.827, respectively. Nucleotide diversity values were high for *vir* 21 ($\pi = 0.04165$, $\Theta_w = 0.03746$) compared to those of other *vir* genes (Table 3; Supplement Fig. 1). Tajima's D values for *vir* 21 were positive (0.40782, $P > 0.1$; Tables 3; Supplement Fig. 2).

In the phylogenetic analysis of *vir* 21, an individual sample collected from CW (v21-11.27) was found. This sample was subjected to BLAST analysis whereupon it showed 99% (952/961) identity with *P. vivax* clone R2_21 (GenBank no. JQ733984.1) from an Indian isolate [24]. Otherwise, the difference between v21-11.27 and the Sal-1 reference gene *vir* 21 was 92% (882/961). With 5 Indian samples R2, R7, G9, G10, and J3 (GeneBank nos. JQ733984.1, JQ733986.1, JQ733975.1, JQ733976.1, and

JQ733981.1, respectively), 2 clades were revealed on phylogenetic tree with almost the same sample sizes of 19 and 20, respectively. Compared with the clade of 19 samples, 20-sample clade had several more subclades (Supplement Fig. 3B).

Variable surface protein 12 gene

Among the 59 samples PCR positive for *vir* 12, there were 74 S. Six were singleton sites with 2 variants, and 68 were parsimony-informative with 2 variants, and 4 were parsimony-informative sites with 3 variants. Distinct nucleotide insertion was found at site 291, CGCTACAGGTTTTC, and a number of nucleotide changes were also found (Fig. 2C). The sequences of *vir* 12 genes are available in GenBank (nos. KY608364-608419). The values of H and Hd were 9 and 0.795, respectively. Nucleotide diversity values (π and Θ_w) of *vir* 12 were 0.03640 and 0.01979, respectively. Tajima's D value for *vir* 12 was 2.89007 ($P < 0.01$; Table 3; Supplement Fig. 2).

The phylogenetic tree of *vir* 12 consisted of 2 separate clades. The main branch contained 3 sub-branches of 2, 15, and 17 samples, respectively. The Sal-1 reference strain was located in a second branch of 25 samples, which was divided into 2 sub-branches: 1 with 12 samples (separated with Sal-1) and the other with 12 samples (Supplement Fig. 3C).

Variable surface protein 4 gene

In the case of the 26 *vir* 4 gene sequences studied, 6 were S. Among nucleotide sequences, changes were found (A278C in 10 isolates, G512A in 1 isolate, and C40T, T456C, A645C, and T742A in all the isolates, respectively) (Fig. 2D). The sequences of *vir* 4 genes are available in GenBank (nos. KY608341-608363). The H and Hd values were 4 and 0.556, respectively. In contrast to other *vir* genes, the π values of *vir* 4 were lower than the Θ_w values ($\pi = 0.00064$, $\Theta_w = 0.00116$). Moreover, *vir* 4 had the only negative Tajima's D value region (Table 3; Supplement Fig. 2).

There was a distinct difference between the *vir* 4 genes of the




Fig. 3. The phylogenetic tree of *vir 4* was inferred using the minimum evolution method. The optimal tree with the sum of branch length = 0.00535425 is shown.

26 ROK samples and that of the Sal-1 reference strain. The ROK clade had 2 groups consisting of 16 samples and 10 samples, respectively. BLAST alignment of the ROK *vir 4* genes resulted in 93-97% identity with *P. vivax* clone M40_4 (GenBank no.: JQ733948.1), D5 (JQ733949.1), G1 (JQ733950.1), G2 (JQ733951.1), and G4 (JQ733952.1) from Indian isolate. With the sequences of Indian isolates, there were common mutation with Korean isolates in T742A with M40, D5, and G1. However, D5 isolate have the only mutation in G871A [24]. Otherwise, the differences between the ROK and Sal-1 *vir 4* genes were 73-79% (Fig. 3).

DNA diversity in regions

The π and Θ_w values were calculated separately for each *vir* gene and region (Table 4). The average π and Θ_w values of all *vir* genes were 0.02027 and 0.01503, respectively. The π values were generally higher than the Θ_w values except for *vir 4* ($\pi = 0.00064$, $\Theta_w = 0.00116$). In the regional analysis, similar to the average values, the π values were higher than the Θ_w values in PJ and CW, but reverse was true for the GP samples.

DISCUSSION

Plasmodium spp. have several mechanisms for host immune evasion [33]. One of them is the *pir* multigene superfamily, such as *kir*, *bir*, *cir*, and *yir* families encoded by *Plasmodium knowlesi*, *Plasmodium berghei*, *Plasmodium chaubadi*, and *Plasmodium yoelii* [24,34-36]. Especially in *P. falciparum*, these genes already studied that encoded several functional proteins known as *ste*

Table 4. Summary statistics for 4 *vir* genes with population

Region	<i>Vir</i> genes (No. of analyzed genes)	Sequence length	Segregating sites (S)	No. of haplotypes (H)	Haplotype diversity (Hd)	Nucleotide diversity		Tajima's D test
						π	Θ_w	
Gimpo (GP)	<i>Vir</i> 27 (9)	1,255 bp	8	4	0.778	0.00178	0.00227	-0.92403
	<i>Vir</i> 21 (4)	974 bp	83	5	1.000	0.04544	0.04426	0.20329
	<i>Vir</i> 12 (7)	1,323 bp	70	4	0.821	0.04043	0.03164	2.89007 ^a
	<i>Vir</i> 4 (4)	1,314 bp	4	2	0.400	0.00119	0.00143	-1.09380
Paju (PJ)	<i>Vir</i> 27 (25)	1,255 bp	10	6	0.788	0.00293	0.00231	0.89090
	<i>Vir</i> 21 (19)	974 bp	86	10	0.758	0.03489	0.02763	1.07769
	<i>Vir</i> 12 (26)	1,323 bp	79	8	0.849	0.03658	0.02469	1.86160 ^a
	<i>Vir</i> 4 (9)	1,314 bp	5	3	0.644	0.00100	0.00132	-0.98485
Cheorwon (CW)	<i>Vir</i> 27 (28)	1,255 bp	7	5	0.771	0.00236	0.00143	1.92777
	<i>Vir</i> 21 (20)	974 bp	144	15	0.957	0.04800	0.04484	0.28890
	<i>Vir</i> 12 (26)	1,323 bp	76	8	0.803	0.03766	0.02359	2.30545 ^b
	<i>Vir</i> 4 (13)	1,314 bp	6	4	0.659	0.00093	0.00141	-1.22712

^a $P < 0.05$.

^b $P < 0.01$.

vor/rif and *var* in *P. falciparum* [24]. This attribute of avoiding host's immune system can affect the severity of malaria infection in falciparum malaria by delay in immune acquisition, cytoadherence, and rosetting phenomenon [37]. A recent study showed that several *vir* genes have some relation with pathogenesis of vivax malaria [7]. Furthermore, *cir* of *P. chaubadi* have functional role in blood stage malaria [35].

In the present study, analysis of the *vir* 27 sequences of all the samples revealed that this gene is more conserved than *vir* 21 and *vir* 12, having the same nucleotide sequences as *vir* 27 of Sal-1 except for the mutations of 10 nucleotides. Gene *vir* 21 was the most polymorphic, as proven in the previous research [17]. In an earlier research, *vir* 12 was described as being the most conserved gene [17]. However, in our ROK samples, *vir* 12 was the second most polymorphic gene with many segregating sites, and high haplotype and nucleotide diversity values. All sequences of *vir* 4 (a member of *vir* subfamily C that is considered to be the most diverse) differed from *vir* 4 of Sal-1 at 6 mutation points. In spite of the reputation of *vir* 4 as the more polymorphic gene than others, this sequences from ROK seemed to be well conserved. It might be already mutated before introduction in the ROK.

The number of segregating sites ranged from as low as 6 (*vir* 4) to as high as 143 (*vir* 21). The segregating sites induced variant changes into amino acid sequences of the samples. Such changes in amino acid sequences might have affected the antigenicity of *P. vivax*, evading the immune system of the host. However, it is not so clear that how *vir* gene superfamilies' really work on the protozoal dodge against the host attack and result in the clinical manifestation of vivax malaria [7].

Diversity parameters were similar to the number of segregating sites. First, the average number of H of all 4 *vir* genes was 10.25, and the average Hd value was 0.738. Gene *vir* 21 (H=22, Hd=0.827) was the most genetically diverse, followed by *vir* 12 (H=9, Hd=0.795), *vir* 27 (H=6, Hd=0.774), and *vir* 4 (H=6, Hd=0.556). The H and Hd values of *vir* 4 were comparatively lower than the others, alike to a previous study in India [25]. Second, the π and Θ_w values of *vir* genes were variable from high to low. It might indicate that there was ongoing molecular mutation among *vir* genes of the ROK malaria isolates.

Tajima's D test was computed for analyzing the natural selection occurrences of the *P. vivax vir* genes from the ROK samples. A positive Tajima D value indicates that an increase of polymorphism, a decrease of population size, and/or balanc-

ing selection can occur. A negative D value means a low frequency of polymorphism, an expansion of population size, and/or purifying selection. The *vir* 4 gene (-1.32162, $P > 0.1$) had the only negative value, indicating that this gene might be under unfavorable circumstance for survival and/or in the process of being purged from the genetic pool via population expansion, an effect that increases with a lower mutation rate but decreases with a higher recombination rate [38]. With this result and the *vir* 4 gene's low PCR-positive rate, the *vir* 4 may be dispreferred to *P. vivax* existing in the endemic region of ROK. Tajima's D values for *vir* 27 (1.08530, $P > 0.1$), *vir* 12 (2.89007, $P < 0.01$), and *vir* 21 (0.40782, $P > 0.1$) were all positive, meaning a population contraction of these genes and a process of balancing selection [39]. Moreover, Tajima's D value for *vir* 12 was statistically significant, indicating that among 4 *vir* genes this gene is under balancing selection and/or decreasing population size. In addition, such value means that *vir* 12 may be the major target of the host immune system in ROK. In the regional analysis, only *vir* 27 samples from GP had negative Tajima's D values differ from the Tajima's D test result of whole samples (-0.92403). In this case, *vir* 27 samples from GP were considered as under purifying selection, or expanding population size situation. However, it is hard to make a conclusion, because there were only 11 case collected. So, further studies will be needed. With the result of the *vir* 21 and *vir* 4 genes, there were some differences between few ROK isolates and Sal-1 *vir* genes. Also, those isolates were very similar to the *vir* genes of Indian isolates. This inferred that *P. vivax* malaria in the ROK might have some relationship with *P. vivax* in India. However, it is hard to clarify this relationship due to lack of knowledge about *vir* gene superfamily.

In the current study, all phylogenetic trees showed clear 2 clades same as previous studies [24,25]. However, because of the randomly scattered sample distribution, there was no particular branching according to the geographical differences and hard to find obvious cluster.

In conclusion, this study was the first survey about the *vir* genes in the ROK, providing information on the genetic level. Among the 4 *vir* genes studied, the *vir* 27 was relatively conserved and expressed widely. Next, the most divergent was *vir* 12 whereas the most conserved was *vir* 4. However, the ROK sample sequences of some *vir* 21 and *vir* 4 showed a clear difference with the Sal-1 reference gene sequence, but were very similar to the *vir* 21 and *vir* 4 genes of Indian isolates. Moreover, several changes on the amino acid level were revealed.

Nevertheless, it was hard to find some trend among the samples according to the period, because the study was conducted only for 3 years. Also, the revelation of the specific function of *vir* gene is not yet sufficient; therefore, applying VSAs from *vir* genes in practical areas is only at the beginning stages, and VSA variances could be an obstacle to achieving a certain product. With these results, however, the information boundary surrounding *vir* genes in the ROK was expanded, thereby advancing the first steps of the buildup the information basis. So, this kind of study about *vir* genes is needed in order to understand vivax malaria, the largest parasitic foe of healthcare.

ACKNOWLEDGMENTS

This work was supported by Biomedical Research Institute grant, Kyungpook National University Hospital (2014). We are grateful to all blood donors and the staff of the Public Health Centers and hospitals in the ROK.

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

REFERENCES

- Dalrymple U, Mappin B, Gething PW. Malaria mapping: understanding the global endemicity of falciparum and vivax malaria. *BMC Med* 2015; 13: 140.
- World Health Organization. World malaria report 2015. Geneva, Switzerland.
- Popovici J, Ménard D. Challenges in antimalarial drug treatment for vivax malaria control. *Trends Mol Med* 2015; 21: 776-788.
- Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. *Am J Trop Med Hyg* 2007; 77: 79-87.
- del Portillo HA, Lanzer M, Rodriguez-Malaga S, Zavala F, Fernandez-Becerra C. Variant genes and the spleen in *Plasmodium vivax* malaria. *Int J Parasitol* 2004; 34: 1547-1554.
- World Health Organization. World malaria report 2013. Geneva, Switzerland. World Health Organization. 2013.
- Gupta P, Sharma R, Chandra J, Kumar V, Singh R, Pande V, Singh V. Clinical manifestations and molecular mechanisms in the changing paradigm of vivax malaria in India. *Infect Genet Evol* 2016; 39: 317-324.
- Kim HC, Pacha LA, Lee WJ, Lee JK, Gaydos JC, Sames WJ, Lee HC, Bradley K, Jeung GG, Tobler SK, Klein TA. Malaria in the Republic of Korea, 1993-2007. Variables related to re-emergence and persistence of *Plasmodium vivax* among Korean populations and U.S. forces in Korea. *Mil Med* 2009; 174: 762-769.
- Kim JY, Goo YK, Zo YG, Ji SY, Trimarsanto H, To S, Clark TG, Price RN, Auburn S. Further evidence of increasing diversity of *Plasmodium vivax* in the Republic of Korea in recent years. *PLoS One* 2016; 11: e0151514.
- Linthicum KJ, Anyamba A, Killenbeck B, Lee WJ, Lee HC, Klein TA, Kim HC, Pavlin JA, Britch SC, Small J, Tucker CJ, Gaydos JC. Association of temperature and historical dynamics of malaria in the Republic of Korea, including reemergence in 1993. *Mil Med* 2014; 179: 806-814.
- Rieckmann K, Davis DR, Hutton DC. *Plasmodium vivax* resistance to chloroquine? *Lancet* 1989; 2: 1183-1184.
- Dua VK, Kar PK, Sharma VP. Chloroquine resistant *Plasmodium vivax* malaria in India. *Trop Med Int Health* 1996; 1: 816-819.
- Añez A, Moscoso M, Laguna Á, Garnica C, Melgar V, Cuba M, Gutierrez S, Ascaso C. Resistance of infection by *Plasmodium vivax* to chloroquine in Bolivia. *Malaria J* 2015; 14: 261.
- Thanh PV, Hong NV, Van NV, Louisa M, Baird K, Xa NX, Peeters Grietens K, Hung le X, Duong TT, Rosanas-Urgell A, Speybroeck N, D'Alessandro U, Erhart A. Confirmed *Plasmodium vivax* resistance to chloroquine in central Vietnam. *Antimicrob Agents Chemother* 2015; 59: 7411-7419.
- Fernandez-Becerra C, Pein O, de Oliveira TR, Yamamoto MM, Cassola AC, Rocha C, Soares IS, de Bragança Pereira CA, del Portillo HA. Variant proteins of *Plasmodium vivax* are not clonally expressed in natural infections. *Mol Microbiol* 2005; 58: 648-658.
- Pasternak ND, Dzikowski R. PfEMP1: an antigen that plays a key role in the pathogenicity and immune evasion of the malaria parasite *Plasmodium falciparum*. *Int J Biochem Cell Biol* 2009; 41: 1463-1466.
- Fernandez-Becerra C, Yamamoto MM, Vêncio RZ, Lacerda M, Rosanas-Urgell A, del Portillo HA. *Plasmodium vivax* and the importance of the subtelomeric multigene *vir* superfamily. *Trends Parasitol* 2009; 25: 44-51.
- Lopez FJ, Bernabeu M, Fernandez-Becerra C, del Portillo HA. A new computational approach redefines the subtelomeric *vir* superfamily of *Plasmodium vivax*. *BMC Genomics* 2013; 14: 8.
- Carvalho BO, Lopes SC, Nogueira PA, Orlandi PP, Bargieri DY, Blanco YC, Mamoni R, Leite JA, Rodrigues MM, Soares IS, Oliveira TR, Wunderlich G, Lacerda MV, del Portillo HA, Araújo MO, Russell B, Suwanarusk R, Snounou G, Rénia L, Costa FT. On the cytoadhesion of *Plasmodium vivax*-infected erythrocytes. *J Infect Dis* 2010; 202: 638-647.
- Bernabeu M, Lopez FJ, Ferrer M, Martin-Jaular L, Razaname A, Corradin G, Maier AG, del Portillo HA, Fernandez-Becerra C. Functional analysis of *Plasmodium vivax* VIR proteins reveals different subcellular localizations and cytoadherence to the ICAM-1 endothelial receptor. *Cell Microbiol* 2012; 14: 386-400.
- Arévalo-Herrera M, Chitnis C, Herrera S. Current status of *Plasmodium vivax* vaccine. *Hum vaccin* 2010; 6: 124-132.
- Makobongo MO, Keegan B, Long CA, Miller LH. Immunization of *Aotus* monkeys with recombinant cysteine-rich interdomain

- region 1 alpha protects against severe disease during *Plasmodium falciparum* reinfection. *J Infect Dis* 2006; 193: 731-740.
23. Chen Q, Pettersson F, Vogt AM, Schmidt B, Ahuja S, Liljeström P, Wahlgren M. Immunization with PfEMP1-DBL1 α generates antibodies that disrupt rosettes and protect against the sequestration of *Plasmodium falciparum*-infected erythrocytes. *Vaccine* 2004; 22: 2701-2712.
 24. Gupta P, Das A, Singh OP, Ghosh SK, Singh V. Assessing the genetic diversity of the *vir* genes in Indian *Plasmodium vivax* population. *Acta Trop* 2012; 124: 133-139.
 25. Gupta P, Pande V, Das A, Singh V. Genetic polymorphisms in *VIR* genes among Indian *Plasmodium vivax* populations. *Korean J Parasitol* 2014; 52: 557-564.
 26. Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE, Thaithong S, Brown KN. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. *Mol Biochem Parasitol* 1993; 61: 315-320.
 27. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. *Nucleic Acids Symp Ser* 1999; 41: 95-98.
 28. Librado P, Rozas J. DnaSP v5: a software for comprehensive analysis of DNA polymorphism data. *Bioinformatics* 2009; 25: 1451-1452.
 29. Watterson GA. On the number of segregating sites in genetical models without recombination. *Theor Popul Biol* 1975; 7: 256-276.
 30. Tajima F. Evolutionary relationship of DNA sequences in finite populations. *Genetics* 1983; 105: 437-460.
 31. Tajima F. Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. *Genetics* 1989; 123: 585-595.
 32. Kumar S, Stecher G, Tamura K. MEGA7: Molecular evolutionary genetics analysis version 7.0 for bigger datasets. *Mol Biol Evol* 2016; 33: 1870-1874.
 33. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA. Key gaps in the knowledge of *Plasmodium vivax*, a neglected human malaria parasite. *Lancet Infect Dis* 2009; 9: 555-566.
 34. Janssen CS, Phillips RS, Turner CM, Barrett MP. *Plasmodium* interspersed repeats: the major multigene superfamily of malaria parasites. *Nucleic Acids Res* 2004; 32: 5712-5720.
 35. Yam XY, Brugat T, Siau A, Lawton J, Wong DS, Farah A, Twang JS, Gao X, Langhorne J, Preiser PR. Characterization of the *Plasmodium* interspersed repeats (*PIR*) proteins of *Plasmodium chabaudi* indicates functional diversity. *Sci Rep* 2016; 6: 23449.
 36. Jackson AP. Gene family phylogeny and the evolution of parasite cell surfaces. *Mol Biochem Parasitol* 2016; 209: 64-75.
 37. A-Elgadir TM, Theander TG, Elghazali G, Nielsen MA, A-Elbasit IE, Adam I, Troye-Blomberg M, Elbashir MI, Giha HA. Determinants of variant surface antigen antibody response in severe *Plasmodium falciparum* malaria in an area of low and unstable malaria transmission. *Scand J Immunol* 2016; 63: 232-240.
 38. Hudson RR, Kaplan NL. Deleterious background selection with recombination. *Genetics* 1995; 141: 1605-1617.
 39. Kang JM, Ju HL, Kang YM, Lee DH, Moon SU, Sohn WM, Park JW, Kim TS, Na BK. Genetic polymorphism and natural selection in the C-terminal 42 kDa region of merozoite surface protein-1 among *Plasmodium vivax* Korean isolates. *Malar J* 2012; 11: 206.